Medical Program: Perspectives on How KEYNOTE-189 is Changing NSCLC Care Paradigms

Perspectives on How KEYNOTE-189 is Changing NSCLC Care Paradigms

Perspectives on How KEYNOTE-189 is Changing NSCLC Care Paradigms
RestartResume
There’s been a pretty significant shift in the way we approach NSCLC care—all thanks to the groundbreaking clinical trial KEYNOTE-189.
  • Overview

    For those non-small cell lung cancer (NSCLC) patients without driver mutations or PD-L expressions, the new care paradigm brought on by KEYNOTE-189 has shown to improve these patients’ progression-free survival rates. Here to break down this clinical trial’s unprecedented findings is Dr. Edward Kim, Chair of Solid Tumor Oncology and Investigational Therapeutics at Levine Cancer Institute.

    Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Facebook Comments

NEW FEATURES:

Register

Join the Global Oncology Academy of learners.
Registration is free and easy.

Register Now